FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference
- PMID: 32653872
- DOI: 10.1515/cclm-2020-0460
FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference
Keywords: FGF23; X-linked hypophosphataemia (XLH); burosumab; immunoassay; interference.
References
-
- Haffner, D, Emma, F, Eastwood, DM, Duplan, BM, Bacchetta, J, Schnabel, D et al. Cinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 2019;15:435–55. https://doi.org/10.1038/s41581-019-0152-5.
-
- Carpenter, TO, Imel, EA, Ruppe, MD, Weber, TJ, Klausner, MA, Wooddell, MM, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest 2014;124:1587–97. https://doi.org/10.1172/jci72829.
-
- Zhang, X, Imel, EA, Ruppe, MD, Weber, TJ, Klausner, MA, Ito, T et al. Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. J Clin Pharmacol 2016;56:176–85. https://doi.org/10.1002/jcph.570.
-
- Fauconnier, C, Roy, T, Gillerot, G, Roy, C, Pouleur, C, Gruson, D. FGF23: Usefulness and analytical evolution. Clin Biochem 2019;66:1–12. 56:176–85. https://doi.org/10.1016/j.clinbiochem.2019.03.002.
-
- Souberbielle, JC, Prié, D, Piketty, ML, Rothenbuhler, A, Delanaye, P, Chanson, P et al. Evaluation of a new fully automated assay for plasma intact FGF23. Calcif Tissue Int 2017;101:510–8. https://doi.org/10.1007/s00223-017-0307-y.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources